Introduction
============

The natural alkaloid camptothecin (**CPT**, [Scheme 1](#molecules-07-00628-f001){ref-type="scheme"}), extracted from *Camptotheca acuminata* by Wall and Wani \[[@B1-molecules-07-00628]\], has demonstrated efficacy in the treatment of several cancers. However, interest in its application as an anti-tumour agent has declined due to its toxic secondary effects. The cellular target of the alkaloid has been shown to be topoisomerase I \[[@B2-molecules-07-00628]\], an enzyme essential for religation of DNA during a number of critical cellular processes, including replication, transcription and repair \[[@B3-molecules-07-00628]\]. Camptothecin, topoisomerase I and DNA form a so-called \"cleavable complex\" \[[@B4-molecules-07-00628]\] that results in topoisomerase I-mediated DNA breaks by preventing DNA religation. These results have prompted the synthesis of a variety of derivatives and analogues of camptothecin. Topotecan (Hycamtin) and irinotecan (Camptosar) are two of the leading examples \[[@B5-molecules-07-00628],[@B6-molecules-07-00628],[@B7-molecules-07-00628]\]. Much effort, including that leading to the two drugs above cited, has been devoted towards increasing the water solubility of the camptothecin analogues in order to obtain compounds with an improved pharmacological profile and enhanced efficacy against human tumors \[[@B8-molecules-07-00628],[@B9-molecules-07-00628],[@B10-molecules-07-00628]\].

![](molecules-07-00628-g001){#molecules-07-00628-f001}

From structure-activity relationship studies \[[@B11-molecules-07-00628]\] it appears that the E-ring lactone and the natural 20S-configuration are essential for anti-tumour activity. While the activity of compounds with substitutions in rings C and D is critically dependent on the size and type of the substituents \[[@B12-molecules-07-00628]\], most structural modifications have concerned rings A and B where wide possibilities of variation exist, especially at positions 7, 9, 10 and 11. Recently the structure of topoisomerase I covalent and non-covalent complexes with a 22-base pair DNA duplex has been solved by X-ray analysis. Based on the crystal structure and structure-activity relationships, a mode of binding for camptothecin has been proposed \[[@B13-molecules-07-00628]\]. In this and in the analogous compound \[[@B14-molecules-07-00628]\], there is plenty of room for substitution at position 7 without steric interference.

A number of camptothecin derivatives have been developed and tested against various cancer cell lines in the past few years and have indicated the importance of lipophilic groups at position 7 of camptothecin for potent cytotoxic activity. The low solubility in water of these compounds does not amount to a grave disadvantage due to the possibility of successful administration *per os* of camptothecin derivatives \[[@B15-molecules-07-00628],[@B16-molecules-07-00628]\].

We report the synthesis and *in vitro* anti-tumour activity of a new series of **OPIC** compounds ([Scheme 1](#molecules-07-00628-f001){ref-type="scheme"}) that are readily separated into their pure diastereoisomers (**3a-d** and **4a-d**). These new **OPIC** compounds, deriving from a pyridyl-oxo cyclisation, can be obtained through a simpler and more economical synthetic method than **CPT**. The starting material, 2,2\'-bipyridine-3,3\'-dicarboxylic acid (**1**), was obtained in good yield from commercial 1,10-phenanthroline by oxidation using the KMnO~4~ procedure described by Ben-Hadda et al \[[@B17-molecules-07-00628]\]. The reaction of **1** with thionyl chloride under an inert atmosphere provides an unstable chloro-addition intermediate, the 3,3\'-dichlorocarbonyl-2,2\'-bipyridine, which is converted into the 3,3'-dialkoxycorbonyl-2,2'-bipyridine (**BPE**) upon addition of the desired alcohol. The same method for the synthesis of **BPE** could be slightly modified and usefully exploited to prepare the new family of **OPIC** compounds.

Results and Discussion
======================

Chemistry
---------

[Scheme 2](#molecules-07-00628-f002){ref-type="scheme"} depicts the general reaction. In our first attempt, oxopyridoindolizine-carboxylates (**OPIC 3**, **4**) were prepared from **BPA** (**1**) and freshly distilled thionyl chloride. After gentle reflux for 5-24 h, followed by subsequent addition of the alcohol, the title compounds were isolated in very poor yield (2-5%). The majority of products (62-93%) were the 3,3\'-dialkoxycarbonyl-2,2\'-bipyridines (**BPE**).

![](molecules-07-00628-g002){#molecules-07-00628-f002}

The use of technical grade thionyl chloride (which contains small amounts of chlorine), under the same conditions as above led to higher, but still modest, yields of the **OPIC** compounds: 3-7% for **3a-d** and 12-31% for **4a-d**. The thionyl chloride contained a small amount of gaseous chlorine, most likely produced *in situ* by thermo and/or photodecomposition of the reagent. This observation led us to believe that the deliberate addition of chlorine would greatly improve the yield of **OPIC**. We found that in addition to improving the yield of **OPIC**, the addition of gaseous chlorine to the reaction decreased the reaction time from 5h to 2h. The optimisation and mechanism of the formation of **OPIC** has been reported recently in more detail \[[@B20-molecules-07-00628]\].

Evaluation of in vitro Anti-tumour Activity
-------------------------------------------

A series of substituted **OPIC** (**3** and **4**) and **BPE** (**2**) differing in the substituents on the carboxylate groups were selected by the National Cancer Institute for evaluation of their *in vitro* anticancer activity ([Table 1](#molecules-07-00628-t001){ref-type="table"}).

molecules-07-00628-t001_Table 1

###### 

*In vitro* cytotoxic activity of selected **OPIC** derivatives against three cell lines.

  ---------- ---------- ------------------------ ---------- ----- ----------
  Compound   R          Growth Percentages^20^   Activity         
  (Lung)     (Breast)   (CNS)                                     
  NCI-H460   MCF7       SF-268                                    
  2b         Et         97                       89         90    Inactive
  2c         i-Pr       105                      90         114   Inactive
  2d         i-Bu       81                       82         74    Inactive
  3c         i-Pr       96                       20         72    Active
  4b         Et         99                       67         96    Inactive
  4c         i-Pr       105                      19         62    Active
  4d         i-Bu       100                      62         100   Inactive
  ---------- ---------- ------------------------ ---------- ----- ----------

From the data in [Table 1](#molecules-07-00628-t001){ref-type="table"} it appears that only the oxopyridoindolizines **3c** and **4c** show any marked cytotoxic activity compared to the rest of series (**3** and **4**). In this case, the degree of lipophilicity of the carboxylate substituent does not correlate positively with the cytotoxic activity. A direct influence of the lipophilic group from the pyridyl nucleus appears to be more important for activity. Compounds **3c** and **4c** were further tested for their *in vitro* activity against 60 cell lines ([Table 2](#molecules-07-00628-t002){ref-type="table"}, [Table 3](#molecules-07-00628-t003){ref-type="table"} and [Table 4](#molecules-07-00628-t004){ref-type="table"}).
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molecules-07-00628-t002_Table 2

###### 

Comparative study of *in vitro* anti-tumour activity of diastereoisomers **3c** and **4c** ([Scheme 3](#molecules-07-00628-f003){ref-type="scheme"}) against leukemia and non-small cell lung cancer cell lines.

  ----------- ----------- ------------- -------------
  Panel       Cell line   GI~50~        
  **3c**      **4c**                    
              HL-60(TB)   2.58x10^-5^   3.82x10^-5^
              K-563       3.34x10^-5^   3.06x10^-5^
  Leukemia    MOLT-4      3.19x10^-5^   2.25x10^-5^
              RPMI-8226   2.98x10^-5^   2.18x10^-5^
              SR          4.96x10^-5^   2.65x10^-5^
              A549/ATCC   \> 10^-4^     \> 10^-4^
              EKVX        \> 10^-4^     \> 10^-4^
              HOP-62      \> 10^-4^     \> 10^-4^
  Non-small   HOP-92      \> 10^-4^     4.63x10^-5^
  cell lung   NCI-H226    \> 10^-4^     \> 10^-4^
              NCI-H23     \> 10^-4^     4.62x10^-5^
              NCI-H322M   \> 10^-4^     \> 10^-4^
              NCI-H460    \> 10^-4^     \> 10^-4^
              NCI-H522    3.57x10^-5^   2.62x10^-5^
  ----------- ----------- ------------- -------------

molecules-07-00628-t003_Table 3

###### 

Comparative *in vitro* anti-tumour activity of diastereoisomers **3c** and **4c** against CNS, melanoma, ovarian and renal cancer cell lines.

  ---------------- ----------- ------------- -------------
  Panel            Cell line   GI~50~        
  **3c**           **4c**                    
                   SF-268      8.21x10^-5^   4.79x10^-5^
                   SF-295      \> 10^-4^     \> 10^-4^
  CNS cancer       SF-539      \> 10^-4^     \> 10^-4^
                   SNB-19      \> 10^-4^     \> 10^-4^
                   U251        \> 10^-4^     5.68x10^-5^
                   LOX IMVI    \> 10^-4^     6.88x10^-5^
                   MALME-3M    \> 10^-4^     2.88x10^-5^
                   M14         \> 10^-4^     \> 10^-4^
                   SK-MEL-2    \> 10^-4^     \> 10^-4^
  Melanoma         SK-MEL-28   \> 10^-4^     \> 10^-4^
                   SK-MEL-5    \> 10^-4^     8.30x10^-5^
                   UACC-257    \> 10^-4^     3.41x10^-5^
                   UACC-62     \> 10^-4^     \> 10^-4^
                   IGROV1      9.63x10^-5^   3.11x10^-5^
                   OVCAR-3     \> 10^-4^     \> 10^-4^
  Ovarian cancer   OVCAR-4     \> 10^-4^     \> 10^-4^
                   OVCAR-5     \> 10^-4^     \> 10^-4^
                   OVCAR-8     3.98x10^-5^   3.17x10^-5^
                   786-0       7.39x10^-5^   5.52x10^-5^
                   A498        \> 10^-4^     \> 10^-4^
                   ACHIN       \> 10^-4^     \> 10^-4^
  Renal cancer     CAKI-1      \> 10^-4^     \> 10^-4^
                   RXF 393     \> 10^-4^     \> 10^-4^
                   SN12C       2.12x10^-5^   2.18x10^-5^
                   TK-10       \> 10^-4^     \> 10^-4^
                   UO-31       \> 10^-4^     \> 10^-4^
  ---------------- ----------- ------------- -------------
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###### 

Comparative *in vitro* anti-tumour activity of diastereoisomers **3c** and **4c** against prostate, breast and colon cancer cell lines.

  ----------------- ----------------- ------------- -------------
  Panel             Cell line         GI~50~        
  **3c**            **4c**                          
                    PC-3              \> 10^-4^     5.66x10^-5^
  Prostate Cancer   DU-145            \> 10^-4^     \> 10^-4^
                    MCF7              8.44x10^-5^   3.91x10^-5^
                    NCI/ADR-RES       \> 10^-4^     \> 10^-4^
  Breast Cancer     MDA-MB-231/ATCC   \> 10^-4^     \> 10^-4^
                    HS 578T           8.15x10^-5^   \> 10^-4^
                    MDA-MB-435        \> 10^-4^     8.10x10^-5^
                    MDA-N             4.41x10^-5^   5.10x10^-5^
                    BT-549            \> 10^-4^     3.69x10^-5^
                    COLO 205          \> 10^-4^     4.39x10^-5^
                    HCC-2998          \> 10^-4^     \> 10^-4^
                    HCT-116           \> 10^-4^     5.06x10^-5^
  Colon Cancer      HCT-15            \> 10^-4^     7.03x10^-5^
                    HT29              \> 10^-4^     \> 10^-4^
                    KM12              \> 10^-4^     \> 10^-4^
                    SW-620            3.49x10^-5^   3.46x10^-5^
  ----------------- ----------------- ------------- -------------

Conclusions
===========

Chlorination of **BPA** with thionyl chloride in the presence of gaseous chlorine has been demonstrated to be a powerful and optimal method for pyridyl-oxo cyclisation in the preparation of a new heterocyclic family; the oxopyridoindolizine carboxylates (**OPIC**). This work provides for the first time a simple one-pot synthetic methodology for the preparation of a wide range of **OPIC** compounds which are analogues or hybrids of the natural alkaloid Camptothecin (**CPT**). The cytotoxic activity of this new family suggests a promising novel approach to the design of prospective compounds for the treatment of cancer.

As a guide for future work, the data reported here indicate that the **OPIC** compounds have a definite potential efficacy that merits development through modification to both the pyridyl and the chlorinated rings. We note, however, that although the compounds are nominally camptothecin analogues there is no necessary presumption that they do in fact resemble camptothecin and thereby target topoisomerase I. It might be possible to address this question by testing their effect(s) on two cell lines, one of which has normal topoisomerase I and the other has a mutant (camptothecin-resistant) enzyme. If there were a difference in GI~50~ value this would indicate that topoisomerase I is a critical target for the drugs. Given the rather low GI~50~ values of the present compounds, around 200 mM, it would be prudent first to seek new derivatives having GI~50~ values around 1 micromolar or less so that the assay can be conducted more efficiently, though the interest in compounds **3c** and **4c** because of their particular stereochemistry remains undiminished. A further consideration relates to the poor solubility of the chloro derivatives in water; for the cell line assays to work it is important to prepare derivatives that are more soluble. Substituting the chloro atoms with some other groups such as alkyloxy or amino is possible and might produce the desired effect.

Experimental
============

General
-------

Melting points are determined by using a Buchi 510 apparatus and are uncorrected. ^1^H- and ^13^C‑NMR spectra were recorded on a Bruker WP-80 operating at 200.131 MHz and AC 250 at 250.14 MHz or an AM 300 at 300.134 MHz spectrometer. The numbering used in the assignment of the NMR spectra is shown in [Scheme 4](#molecules-07-00628-f004){ref-type="scheme"}. Mass spectra were recorded on a Platform II Micro Mass spectrometer, and FTIR spectra on a Nicolet 205 instrument.

General procedure for the synthesis of 3,3\'-di-alkyloxycarbonyl-2,2\'-bipyridines (**BPE**: **2**) and alkyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido \[2,3-a\]indolizine-10-carboxylates (**OPIC**: **3** and **4**).
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The 3,3\'-dihydroxycarbonyl-2,2\'-bipyridine (**1**) used in this work was prepared from 1,10-phenanthroline **1** by a procedure described previously \[[@B17-molecules-07-00628]\]. 2,2\'-bipyridine-3,3\'-dicarboxylic acid (BPA, 600 mg, 2.5 mmol) was added to technical grade thionyl chloride (10 mL) and the mixture was refluxed for 1 h. The excess thionyl chloride was removed under vacuum to leave a yellow residue. Toluene (20 mL) and an alcohol (ROH, 1 mL) were added and the solution was heated under reflux for 3 h. Chloroform (40 mL) was added and the organic phase was washed with a cooled solution of sodium bicarbonate (2.5%). The organic layer was dried over sodium sulfate and the chloroform was removed under reduced pressure. The crude product was purified on a silica gel column (l = 30 cm, q = 3 cm). Three white solids were successively obtained. Compound **4** was eluted first using a (10:90) mixture of petroleum ether/dichloromethane. Derivative **3** eluted next using a 5;95 ratio of ether/dichloromethane. Finally, the diester **2** was recovered by elution with (40:60) ether/acetone.

![Labelling used for NMR assignments \[**a** (R = Me), **b** (R = Et), **c** (R = i-Pr), **d** (R = i-Bu)\]](molecules-07-00628-g004){#molecules-07-00628-f004}

*3,3\'-di-Methoxycarbonyl-2,2\'-bipyridine* (**2a**) : Yield 52%; white powder; m.p. 135-136 °C; ^1^H-NMR (250.14 MHz, CDCl~3~) d: 8.74 (dd, 2 H, H~6~/H~6~\', ^3^J~H6-H5~ = 4.83 Hz, ^4^J~H6-H4~ = 1.62 Hz), 8.37 (dd, 2 H, H~4~/H~4~\', ^3^J~H4-H5~ = 7.94 Hz, ^4^J~H4-H6~ = 1.62 Hz), 7.44 (dd, 2 H, H~5~/H~5~\', ^3^J~H5-H4~ = 7.94 Hz, ^3^J~H5-H6~ = 4.83 Hz), 3.66 (s, 6 H, 2 CH~3~); Analysis, Calcd. (Found) for C~14~H~12~N~2~O~4~: C 61.76 (60.13), H 4.42 (4.45), N 10.29 (9.82); MS m/z: 273.0 (Calcd for C~14~H~12~N~2~O~4~ : 272.26). IR (KBr) n cm^-1^: 1720 (C=O, s), 1582, 1582 (C=C, m), 1440 (C=N, m), 1307, 1299 (C-O, m).

*3,3\'-di-Ethoxycarbonyl-2,2\'-bipyridine* (**2b**): Yield 81%; white powder; m.p. 89-90 °C; ^1^H-NMR (250.14 MHz, CDCl~3~) d ppm: 8.74 (dd, 2 H, H~6~/H~6~\', ^3^J~H6-H5~ = 4.80 Hz, ^4^J~H6-H4~ = 1.56 Hz), 8.36 (dd, 2 H, H~4~/H~4~\', ^3^J~H4-H5~ = 7.93 Hz, ^4^J~H4-H6~ = 1.56 Hz), 7.42 (dd, 2 H, H~5~/H~5~\', ^3^J~H5-H4~ = 7.93 Hz, ^3^J~H5-H6~ = 4.80Hz), 4.08 (qu, 4 H, 2 CH~2~, ^3^J~CH2-CH3~ = 7.15 Hz), 1.02 (t, 6 H, 2 CH~3~, ^3^J~CH3-CH2~ = 7.15 Hz); Analysis, Calcd. (Found) for C~16~H~16~N~2~O~4~: C 64.01 (63.56.), H 5.33 (5.62), N 9.33 (9.13); MS m/z : 301.10 (Calcd. for C~16~H~16~N~2~O~4~ : 300.316). IR (KBr) n cm^-1^: 1724 (C=O, s), 1578, 1565 (C=C, w), 1423 (C=N, m), 1277 (C-O, w).

*3,3\'-di-iso-Propyloxycarbonyl-2,2\'-bipyridine* (**2c**): Yield 73%; white powder; m.p. 81-82 °C; ^1^H‑NMR (250.14 MHz, CDCl~3~) d ppm: 8.73 (dd, 2 H, H~6~/H~6~\', ^3^J~H6-H5~ = 4.80 Hz, ^4^J~H6-H4~ = 1.70 Hz), 8.37 (dd, 2 H, H~4~/H~4~\', ^3^J~H4-H5~ = 7.93 Hz, ^4^J~H4-H6~ = 1.70 Hz), 7.42 (dd, 2 H, H~5~/H~5~\', ^3^J~H5-H4~ = 7.93 Hz, ^3^J~H5-H6~ = 4.80 Hz), 4.95 (qu, 2 H, CH, ^3^J~CH-CH3~ = 6.31 Hz), 0.97 (d, 12 H, 4 CH~3~, ^3^J~CH3-CH~ = 6.31 Hz); Analysis Calcd. (Found) for C~18~H~20~N~2~O~4~: C 65.85 (65.78.), H 6.10 (6.22), N 8.53 (8.38); MS m/z : 329.10 (Calcd. for C~18~H~20~N~2~O~4~ : 328.371); IR (KBr) n cm^-1^: 1695 (C=O, s), 1535, 1565 (C=C, w), 1415 (C=N, m), 1260 (C-O, w).

*3,3\'-di-iso-Butyloxycarbonyl-2,2\'-bipyridine* (**2d**): Yield 78%; white powder; m.p. 88-89 °C; ^1^H-NMR (250.14 MHz, CDCl~3~) d ppm: 8.74 (dd, 2 H, H~6~/H~6~\', ^3^J~H6-H5~ = 4.83 Hz, ^4^J~H6-H4~ = 1.66 Hz), 8.37 (dd, 2 H, H~4~/H~4~\', ^3^J~H4-H5~ = 7.93 Hz, ^4^J~H4-H6~ = 1.66 Hz), 7.44 (dd, 2 H, H~5~/H~5~\', ^3^J~H5-H4~ = 7.93 Hz, ^3^J~H5-H6~ = 4.83 Hz), 3.84 (d, 2 H, CH~2~, ^3^J~CH-CH2~ = 6.6 Hz), 1.68 (m, 2 H, 2 CH), 0.76 (d, 12 H, 4 CH~3~, ^3^J~CH3-CH~ = 6.6 Hz); Analysis, Calcd. (Found) for C~20~H~24~N~2~O~4~: C 67.42 (67.55), H 6.74 (6.82), N 7.86 (7.87); MS m/z: 357.10 (Calc. for C~20~H~24~N~2~O~4~ : 356.425); IR (KBr) n cm^-1^ : 1713 (C=O, s), 1589/1561 (C=C, w), 1470 (C=N, m), 1289 (C-O, w).

*(7R,8R,9S)-Methyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10-carboxylate* (**3a**): Yield 7%; white powder; m.p. 125-126 °C; ^1^H-NMR (200,131 MHz; CDCl~3~) d ppm: 8.86 (dd, 1 H, H~2~, ^3^J~H2-H3~ = 4.9 Hz, ^4^J~H2-H4~ = 1.6 Hz), 8.14 (dd, 1 H, H~4~, ^3^J~H4-H3~ = 7.8 Hz, ^4^J~H4-H2~ = 1.6 Hz), 7.48 (dd, 1 H, H~3~, ^3^J~H3-H4~ = 7.8 Hz, ^3^J~H3-H2~ = 4.9 Hz), 6.47 (d, 1 H, H~8~, ^3^J~H8-H9~ = 3 Hz), 5.26 (d, 1 H, H~10~, ^3^J~H10-H9~ = 9.8 Hz), 4.52 (dd, 1 H, H~9~, ^3^J~H9-H8~ = 3.05 Hz, ^3^J~H9-H10~ = 9.75 Hz), 3.96 (s, 3 H, CH~3~); MS m/z: 347.0 (Calcd. for C~13~H~9~N~2~O~3~Cl~3~: 346.60). IR (KBr) n cm^-1^: 1744 (C=O, s), 1715 (C=O, s), 1604,1584 (C=C, w), 1437 (C=N, m), 1292 (C-O, w).

*(7R,8R,9S)-Ethyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10-carboxylate* (**3b**): Yield 4%; white powder; m.p. 104-106 °C; ^1^H-NMR (200.131 MHz, CDCl~3~) d ppm: 8.85 (dd, 1 H, H~2~, ^3^J~H2-H3~ = 4.8 Hz, ^4^J~H2-H4~ = 1.6 Hz), 8.14 (dd, 1 H, H~4~, ^3^J~H4-H3~ = 7.8 Hz, ^4^J~H4-H2~ = 1.6 Hz), 7.48 (dd, 1 H, H~3~, ^3^J~H3-H4~ = 7.8 Hz, ^3^J~H3-H2~ = 4.8 Hz), 6.46 (d, 1 H, H~8~, ^3^J~H8-H9~ = 3.2 Hz), 5.305 (d, 1 H, H~10~, ^3^J~H10-H9~ = 9.8 Hz), 4.53 (dd, 1 H, H~9~, ^3^J~H9-H8~ = 3.2 Hz, ^3^J~H9-H10~ = 9.8 Hz), 4.46 (m, 2 H, CH~2~, ^3^J = 7.12 Hz), 1.37 (t, 3 H, CH~3~, ^3^J = 7.12 Hz); MS m/z : 360.9 (Calcd. for C~14~H~11~N~2~O~3~Cl~3~ : 360.63); IR (KBr) n cm^-1^ : 1752 (C=O, s), 1718 (C=O, s), 1604, 1583 (C=C, w), 1457 (C=N, m).

*(7R,8R,9S)-iso-Propyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10-carboxylate* (**3c**): Yield 6%; white powder; m.p. 99-102 °C; ^1^H-NMR (200.131 MHz, CDCl~3~) d ppm: 8.83 (dd, 1 H, H~2~, ^3^J~H2-H3~ = 4.8 Hz, ^4^J~H2-H4~ = 1.4 Hz), 8.12 (dd, 1 H, H~4~, ^3^J~H4-H3~ = 7.7 Hz, ^4^J~H4-H2~ = 1.4 Hz), 7.51 (dd, 1 H, H~3~, ^3^J~H3-H4~ = 7.7 Hz, ^3^J~H3-H2~ = 4.8 Hz), 6.47 (d, 1 H, H~8~, ^3^J~H8-H9~ = 3.03 Hz), 5.33 (m, 1 H, H~13~), 5.26 (d, 1 H, H~10~, ^3^J~H10-H9~ = 9.7 Hz), 4.52 (dd, 1 H, H~9~, ^3^J~H9-H8~ = 3.03 Hz, ^3^J~H9-H10~ = 9.76 Hz), 1.39 (d, 3 H, CH~14~, ^3^J = 6.2 Hz), 1.34 (d, 3 H, H~14~, ^3^J = 6.2 Hz); MS m/z : 374.90 (Calcd. for C~15~H~13~N~2~O~3~Cl~3~ : 374.653); IR (KBr) n cm^-1^: 1745 (C=O, s), 1715 (C=O, s), 1603, 1584 (C=C, w), 1392 (C=N, m). The crystallographic structure of **3c** has been recently reported \[[@B22-molecules-07-00628]\].

*(7R,8R,9S)-iso-Butyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10---carboxylate* (**3d**): Yield 3%; white powder; m.p. 95-97 °C; ^1^H-NMR (200.131 MHz, DCCl~3~) d ppm: 8.90 (dd, 1 H, H~2~, ^3^J~H2-H3~ = 4.86 Hz, ^4^J~H2-H4~ = 1.6 Hz), 8.18 (dd, 1 H, H~4~, ^3^J~H4-H3~ = 7.8 Hz, ^4^J~H4-H2~ = 1.6 Hz), 7.52 (dd, 1 H, H~3~, ^3^J~H3-H4~ = 7.8 Hz, ^3^J~H3-H2~ = 4.86 Hz), 6.52 (d, 1 H, H~8~, ^3^J~H8-H9~ = 3.07 Hz), 5.26 (d, 1 H, H~10~, ^3^J~H10-H9~ = 9.75 Hz), 4.56 (dd, 1 H, H~9~, ^3^J~H9-H8~ = 3.08 Hz; ^3^J~H9-H10~ = 9.75 Hz), 4.21 (m, 2 H, CH~2~, ^3^J = 6.67 Hz), 2.09 (m, 1 H, CH, ^3^J = 6.7 Hz), 1.04 (d, 6 H, 2 CH~3~, ^3^J = 6.7 Hz); IR (KBr) l cm^-1^: 1750 (C=O, s), 1715 (C=O, s), 1582 (C=C, w), 1473 (C=N, m); MS m/z : 388.90 (Calc. for C~16~H~15~N~2~O~3~Cl~3~ : 388.68); IR (KBr) n cm^-1^ : 1751 (C=O, s), 1713 (C=O, s), 1584 (C=C, w), 1475 (C=N, m).

*(7S,8R,9S)-Methyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10\--carboxylate* (**4a**): Yield 31%; white powder; m.p. 121-122 °C; ^1^H-NMR (250,14 MHz; CDCl~3~) d ppm: 8.9 (dd, H~2~, ^3^J~H2-H3~ = 4.9 Hz, ^4^J~H2-H4~ = 1.6 Hz), 8.2 (dd, 1 H, H~4~, ^3^J~H4-H3~ = 7.8 Hz, ^4^J~H4-H2~ = 1.6 Hz), 7.53 (dd, 1 H, H~3~, ^3^J~H3-H4~ = 7.8 Hz, ^3^J~H3-H2~ = 4.9 Hz), 6.49 (dd, 1 H, H~8~, ^3^J~H8-H9~ = 1.33 Hz, ^4^J~H8-H10~ = 2.1 Hz), 5.35 (t, 1 H, H~9~, ^3^J~H9-H8~ = 1.33 Hz, ^3^J~H9-H10~ = 1.33 Hz), 5.03 (dd, 1 H, H~10~, ^3^J~H10-H9~ = 1.33 Hz, ^4^J~H8-H10~ = 2.1 Hz), 4.0 (s, 3 H, CH~3~); Analysis Calcd. (Found) for C~13~H~9~N~2~O~3~Cl~3~: C 44.94 (44.98), H 2.59 (2.63), N 8.06 (7.99); MS m/z: 347.0 (Calcd. for C~13~H~9~N~2~O~3~Cl~3~: 346.60); IR (KBr) n cm^-1^: 1744 (C=O, s), 1717 (C=O, s), 1601-1581 (C=C, w), 1434 (C=N, m), 1297 (C-O, w).

*(7S,8R,9S)-Ethyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10\--carboxylate* (**4b**): Yield 12%; white powder; m.p. 102-103 °C; ^1^H-NMR (300.134 MHz, CDCl~3~) d ppm: 8.90 (dd, 1 H, H~2~, ^3^J~H2-H3~ = 4.8 Hz, ^4^J~H2-H4~ = 1.6 Hz), 8.21 (dd, 1 H, H~4~,^3^J~H4-H3~ = 7.8 Hz, 4J~H4-H2~ = 1.6 Hz), 7.53 (dd, , 1 H, H~3~, ^3^J~H3-H4~ = 7.8 Hz, ^3^J~H3-H2~ = 4.8 Hz), 6.49 (dd, 1 H, H~8~, ^3^J~H8-H9~ = 1.45 Hz, ^4^J~H8-H10~ = 2.04 Hz), 5.35 (t, 1 H, H~9~, ^3^J~H9-H8~ = 1.42 Hz, ^3^J~H9-H10~ = 1.45 Hz), 5.00 (dd, 1 H, H~10~, ^3^J~H10-H9~ = 1.45 Hz, ^4^J~H10-H8~ = 2.04 Hz), 4.48 (m, 2 H, CH~2~, ^3^J = 7.12 Hz), 1.39 (t, 3 H, CH~3~, ^3^J = 7.12 Hz). {^1^H} ^13^C NMR (MHz, CDCl~3~) d ppm: 154.5 (C~2~), 132.2 (C~4~), 125.2 (C~3~), 62.5 (C~13~), 60.8 (C~8~), 52.8 (C~10~), 57.1 (C~9~), 14.5 (C~14~); Analysis, Calcd. (Found) for C~14~H~11~N~2~O~3~Cl~3~: C 46.97 (47.44), H 3.05 (3.33), N 7.74 (7.35); MS m/z: 360.9 (Calcd. for C~14~H~11~NO~3~Cl~3~ : 360.63); IR (KBr) n cm^-1^ : 1750 (C=O, s), 1716 (C=O, s), 1609, 1580 (C=C, w), 1457 (C=N, m). The crystallographic structure of **4b** has been reported \[[@B20-molecules-07-00628]\].

*(7S,8R,9S)-iso-Propyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10-carboxylate* (**4c**): Yield 12%; white powder; m.p. 97-99 °C; ^1^H-NMR (300.134 MHz, CDCl~3~) d ppm: 8.90 (dd, 1 H, H~2~, ^3^J~H2-H3~ = 4.8 Hz, ^4^J~H2-H4~ = 1.43 Hz), 8.21 (dd, 1 H, H~4~,^3^J~H4-H3~ = 7.8 Hz, 4J~H4-H2~ = 1.43 Hz), 7.53 (dd, 1 H, H~3~, ^3^J~H3-H4~ = 7.8 Hz, ^3^J~H3-H2~ = 4.8 Hz), 6.48 (dd, 1 H, H~8~, ^3^J~H8-H9~ = 1.4 Hz, ^4^J~H8-H10~ = 2.1 Hz), 5.34 (t, 1 H, H~9~, ^3^J~H9-H8~ = 1.4 Hz, ^3^J~H9-H10~ = 1.4 Hz), 5.35 (m, 1 H, H~13~), 1.38 (d, 3 H, CH~3~, ^3^J = 6.2 Hz), 1.32 (d, 3 H, CH~3~, ^3^J = 6.3 Hz); Analysis Calcd. (Found) for C~15~H~13~N~2~O~3~Cl~3~: C 47.97 (47.96), H 3.46 (3.52), N 7.46 (7.39); MS m/z : 374.90 (Calcd. for C~15~H~13~N~2~O~3~Cl~3~: 374.653); IR (KBr) n cm^-1^: 1741 (C=O, s), 1711 (C=O, s), 1600, 1582 (C=C, w), 1396 (C=N, m).

*(7S,8R,9S)-iso-Butyl-7,8,9-trichloro-6,7,8,9-tetrahydro-5-oxopyrido\[2,3-a\]indolizine-10\--carboxylate* (**4d**): Yield 16%; white powder; m.p. 96-97°C; ^1^H -NMR (200.131 MHz, DCCl~3~) d ppm: 8.88 (dd, 1 H, H~2~, ^3^J~H2-H3~ = 4.86 Hz, ^4^J~H2-H4~ = 1.6 Hz), 8.21 (dd, 1 H, H~4~, ^3^J~H4-H3~ = 7.8 Hz, ^4^J~H4-H2~ = 1.6 Hz), 7.52 (dd, 1 H, H~3~, ^3^J~H3-H4~ = 7.8 Hz, ^3^J~H3-H2~ = 4.86 Hz), 6.50 (dd, 1 H, H~8~, ^3^J~H8-H9~ = 1.39 Hz, ^4^J~H8-H10~ = 2.04 Hz), 5.36 (t, 1 H, H~9~, ^3^J~H9-H8~ = 1.39 Hz, ^3^J~H9-H10~ = 1.39 Hz), 5.03 (dd, 1 H, H~10~, ^3^J~H10-H9~ = 1.39 Hz, ^4^J~H10-H8~ = 2.04 Hz), 4.22 (m, 2 H, CH~2~, ^3^J = 6.7 Hz), 2.09 (m, 1 H, H~14~, ^3^J = 6.7 Hz), 1.0 (d, 6 H, 2 CH~3~, ^3^J = 6.7 Hz); Analysis Calcd. (Found) for C~16~H~15~N~2~O~3~Cl~3~: C 49.32 (49.23), H 3.85(3.89), N 7.19 (6.99); MS m/z: 388.90 (Calc. for C~16~H~15~N~2~O~3~Cl~3~ : 388.68); IR (KBr) n cm^-1^ : 1750 (C=O, s), 1715 (C=O, s), 1582 (C=C, w), 1473 (C=N, m).

This work was supported by grants from the Ministry of Education of Morocco (PROTARS No. P1T2/27), Cancer Research U.K., France (AI N° 98/ 160/ SM), and Willaya of Oujda. We wish to thank Professor Bruce Baguley, University of Auckland School of Medicine, New Zealand, for helpful discussions. We would also like to thank Advanced Chemistry Development, Inc., Toronto, Canada for the free on-line nomenclature of organic compounds. We are indebted to TAACF and NCI of USA for biological tests.

*Sample Availability:* Not available.
